Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts

Molecular Cancer Therapeutics

Volumn 12, Issue 4, 2013, Pages 481-490

  Pratt, Susan E ^a   Durland Busbice, Sara ^a   Shepard, Robert L ^a   Donoho, Gregory P ^a   Starling, James J ^a   Wickremsinhe, Enaksha R ^a   Perkins, Everett J ^a   Dantzig, Anne H ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOXYLESTERASE; CARBOXYLESTERASE 2; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; GEMCITABINE; LY 2334737; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON CANCER; COLON TUMOR; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG UPTAKE; FEEDING; GENE EXPRESSION; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MESOTHELIOMA; METRONOMIC DRUG ADMINISTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADMINISTRATION, METRONOMIC; ADMINISTRATION, ORAL; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DEOXYURIDINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HCT116 CELLS; HUMANS; LUNG NEOPLASMS; MICE; PRODRUGS; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876493859     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0654     Document Type: Article

References (50)

1. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51: 6110-7.
2. Heinemann V, Xu Y-Z, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Cellular elimination of 2′, 2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992; 52: 533-9.
3. Heinemann V, Xu Y-Z, Chubb S, Sen A, Hertel L, GB G, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′, 2′-difluorodeox- ycytidine. Mol Pharmacol 1990; 38: 567-72. (Pubitemid 20356209)
4. Wang J, Lohman GJS, Stubbe J. Enhanced subunit interactions with gemcitabine-5′-diphosphate inhibit ribonucleotide reductases. Proc Natl Acad Sci USA 2007;104:14324-9. (Pubitemid 350003260)
5. Sakamoto H, Kitano M, Suetomi Y, Takeyama Y, Ohyanagi H, Nakai T, et al. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol 2006;41:70-6.
6. Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H, Lenzi R, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21: 3402-8. (Pubitemid 46594072)
7. Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, et al. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 2008; 14:3477-86.
8. Horton ND, Young JK, Perkins EJ, Truex LL. Toxicity of single-dose oral gemcitabine in mice [abstract #2115]. Am Assoc Canc Res 2004;45:486.
9. Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA, et al. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem 2009;52:6958-61.
10. Koolen SLW, Witteveen PO, Jansen RS, Langenberg MHG, Krone-meijer RH, Nol A, et al. Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res 2011;17:6071-82.
11. Pratt SE, Durland-Busbice S, Shepard RL, Heinz-Taney K, Dantzig AH. Human carboxylesterase 2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res 2013. [Epub ahead of print].
12. Sanghani S, Sanghani P, Schiel M, Bosron W. Human carboxyles-terases: an update on CES1, CES2 and CES3. Protein Pept Lett 2009;16:1207-14.
13. Kerbel R, Kamen B. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36. (Pubitemid 38745528)
14. Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006;24:3623-8. (Pubitemid 46630536)
15. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-6. (Pubitemid 36951001)
16. Francia G, Shaked Y, Hashimoto K, Sun J, Yin M, Cesta C, et al. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes anti-tumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther 2012;11:680-9.
17. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000;18:343-54.
18. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40:85-104. (Pubitemid 32242792)
19. Gelmon K, Chan A, Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 2006;11:42-51.
20. Hirsch B, Zafar S. Capecitabine in the management of colorectal cancer. Cancer Manag Res 2011;3:79-89.
21. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemci-tabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-8.
22. Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 2010;17: 445-53.
23. Merriman R, Hertel L, Schultz R, Houghton P, Houghton J, Rutherford P, et al. Comparison of the antitumor activity of gemcitabine and ara-c in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 1996;14:243-7. (Pubitemid 26383937)
24. Fiebig HH, Schuchhardt C, Henss H, Fiedler L, Lohr GW. Comparison of tumor response in nude mice and in the patients. Behring Inst Mitt 1984;74:343-52.
25. Garber K. From human to mouse and back: "tumorgraft" models surge in popularity. J Natl Cancer Inst 2008;101:6-8.
26. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56:4171-9. (Pubitemid 26305012)
27. Burkholder T, Clayton J, Rempala M, Henry J, Knobeloch J, Mendel D, et al. Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-FLT-3-internal tandem duplication mutant human tumor xenograft model. Invest New Drugs 2011;30: 936-49.
28. Fiebig HH, Schuler J, Bausch N, Hofmann M, Metz T, Korrat A. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. Cancer Genomics Proteomics 2007;4:197-210. (Pubitemid 46807344)
29. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004;64:3761-6. (Pubitemid 38697284)
30. Bergman AM, Eijk PP, Ruiz van Haperen VWT, Smid K, Veerman G, Hubeek I, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005;65:9510-6. (Pubitemid 41508021)
31. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, et al. Ribonucleotide reductase messenger rna expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004;10:1318-25. (Pubitemid 38365223)
32. Blaheta RA, Cinatl JJ. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002;22:492-511.
33. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O, et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004;18:1246-51. (Pubitemid 39023135)
34. Ward J, Sherali A, Mo Z, Tse C. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside deficient PH12 cells. ENT2 exhibits low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem 2000;275:8375-81. (Pubitemid 30180179)
35. Veltkamp SA, Beijnen JH, Schellens JHM. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist 2008;13:261-76. (Pubitemid 351679901)
36. Veerman G, Ruiz van Haperen VWT, Vermorken JB, Noordhuis P, Braakhuis BJM, Pinedo HM, et al. Antitumor activity of prolonged as compared with bolus administration of 2′, 2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996;38:335-42.
37. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW. Metabolism and disposition of gemcitabine, and oncolytic deox-ycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 1992;20: 849-55.
38. Quinney SK, Sanghani SP, Davis WI, Hurley TD, Sun Z, Murry DJ, et al. Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther 2005;313:1011-6. (Pubitemid 40727004)
39. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase iso-forms hCE-1 and hCE-2. Cancer Res 2000;60:1189-92. (Pubitemid 30151980)
40. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Can Res 2002;8:2605-11. (Pubitemid 34856347)
41. Sanghani SP, Quinney SK, Fredenburg TB, Sun Z, Davis WI, Murry DJ, et al. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin Can Res 2003;9:4983-91. (Pubitemid 37323305)
42. Holzer T, Heinz-Taheny K, Ballard DW, Powell EL, Dolled-Filhart MP, Christiansen J, et al. Potential for patient tailoring for prodrug of gemcitabine (LY2334737) by assessment carboxylesterase II expression in solid tumor biopsies. AACR International Conference Transla-tional Cancer Medicine. San Francisco, California. Clin Cancer Res; 2010:B31.
43. Kotsakis A, Yousem S, Gadgeel SM. Is histologic subtype significant in the management of NSCLC? Open Lung Cancer J 2010;3:66-72.
44. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006;66:3928-35.
45. Damaraju VL, Sawyer MB, Mackey JR, Young JD, Cass CE. Human nucleoside transporters: biomarkers for response to nucleoside drugs. Nucleos Nucleot Nucl 2009;28:450-63.
46. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136:187-95.
47. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydro-genase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685-90. (Pubitemid 28099478)
48. Pressacco J, Mitrovski B, Erlichman C, Hedley DW. Effects of thymi-dylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 1995;55:1505-8.
49. Nakahira S, Nakamori S, Tsujie M, Takeda S, Sugimoto K, Takahashi Y, et al. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res 2008;28:179-86. (Pubitemid 351362899)
50. Sawada N, Fujimoto-Ouchi K, Ishikawa T. Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capeci-tabine plus gemcitabine in human tumor xenograft models. In: Proc Am Assoc Cancer Res 2002;1088a (abstr 5388).